Morning Trend | SUNSHINE PHARMA under pressure, when will the oversold rebound window arrive?

As of the close on January 21, Dongyangguang Pharmaceutical (6887.HK) fluctuated weakly at a low level throughout the day, with sporadic buying on the market and no significant capital inflow observed. The atmosphere of wait-and-see remains strong. The short-term MACD death cross pressure is significant, with green bars continuously extending. Although there is an oversold condition, the main capital has not shown clear buying actions. The entire biopharmaceutical sector has been dragged down by medical insurance centralized procurement and policy adjustments, leading to a significant decline in investment enthusiasm. Dongyangguang Pharmaceutical also has no major clinical progress or large order news disclosed, and the sector's speculative points have cooled down from last year's highs. Strategic funds tend to favor short-term trading of intraday fluctuations, with no clear willingness to hold overnight positions, and market risk appetite continues to decline. 12.10 yuan has become a key observation point for the short term, and a volume contraction below this level indicates that the bearish forces still have room for release. The intraday chart occasionally shows technical rebounds, but the trading volume has not been effectively amplified, lacking sustained follow-up buying. In the overall weak pattern, the oversold rebound window still needs to wait for sector funds and industry event catalysts. In the short term, it is recommended to pay attention to sector fund dynamics, new drug research and development progress, and policy news. Before market sentiment repairs or event-driven signals appear, right-side traders should still prioritize safety margins to prevent additional losses from short-term abnormal fluctuations